US FDA halts Sun Pharma’s trials on dermatological drug, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The FDA has also said that patients with alopecia areata, an autoimmune condition that results in patchy hair loss, on the 12 mg dose of the drug deuruxolitinib should discontinue its use, Sun Pharma said. However, there were no thrombotic events, or blood clot formations, in patients taking the 8 mg dose and the FDA has not placed those trials on hold, Sun Pharma said., The FDA has also said that patients with alopecia areata, an autoimmune condition that results in patchy hair loss, on the 12 mg dose of the drug deuruxolitinib should discontinue its use, Sun Pharma said. However, there were no thrombotic events, or blood clot formations, in patients taking the 8 mg dose and the FDA has not placed those trials on hold, Sun Pharma said., , Read More